---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-038028"
form_type: "8-K"
ticker: "OCGN"
cik: "0001372299"
company_name: "Ocugen, Inc."
filed_at: "2023-11-09T23:59:59+00:00"
generated_at: "2026-06-08T06:18:21.471576+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Ocugen Q3 net loss $0.06/sh; OCU400 shows 83% stabilization rate; OCU500 selected by NIH

## Summary
- Q3 2023 net loss $0.06 per share vs $0.10 year ago; cash $53.5M, down from $90.9M at Dec 2022.
- OCU400 Phase 1/2: 83% (10/12) subjects stabilized/improved in BCVA, LLVA, or MLMT; 86% (6/7) RHO subjects improved MLMT.
- Completed dosing three LCA patients including pediatric; Phase 3 for RP expected early 2024.
- OCU500 (mucosal COVID vaccine) selected by NIH/NIAID Project NextGen for clinical trial inclusion.
- OpEx $15.4M in Q3 2023 vs $23.1M in Q3 2022; R&D $6.3M, G&A $9.1M.

## SEC filing metadata
- accession: 0001628280-23-038028
- form_type: 8-K
- ticker: OCGN
- cik: 0001372299
- company_name: Ocugen, Inc.
- filed_at: 2023-11-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1372299/000162828023038028/0001628280-23-038028-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1372299/000162828023038028/ocgn-20231109.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-038028
- JSON: https://secwatch.observer/filing/0001628280-23-038028.json
- Plain text: https://secwatch.observer/filing/0001628280-23-038028.txt

## Key facts
- Earnings Releases
  Ocugen, Inc. reported third quarter 2023 results: EPS $0.06 net loss per common share.
  - Period: third quarter 2023
  - EPS: $0.06 net loss per common share
  - Result: reported results
  source text: Ocugen reported a $0.06 net loss per common share for the three months ended September 30, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1372299/000162828023038028/0001628280-23-038028-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.